Navigation Links
transOMIC technologies Releases Tagged ORF Clones for Protein Expression

Huntsville, AL (PRWEB) January 29, 2013

transOMIC technologies announced today that it has partnered with Clontech (a Takara Bio company) to launch the MGC premier™ Tagged ORF collections for gene and protein analysis. Over 40,000 human, mouse and rat genes are represented in these new genome-scale ORF collections, making transOMIC technologies the largest provider of gene content for protein expression.

“Introducing this new collection of ORF expression vectors supports our mission to offer new gene analysis tools to the market,” said Blake Simmons, chief executive officer of transOMIC technologies. “By using Clontech’s validated expression system and fusion-tags, we can now provide ready-to-express gene content to simplify gene and protein analysis.”

transOMIC technologies was recently made an archive site for full-length cDNA collections in the NIH’s Mammalian Gene Collection. The company has significantly expanded the utility of this resource with the MGC premier™ Expression-Ready cDNA clone collection in 2012 and now in 2013 with the MGC premier Tagged ORFs for protein expression.

transOMIC technologies’ partnership with Clontech combines industry leading expertise in the development of gene expression systems with transOMIC’s extensive gene content. These vectors contain validated fusion tags that minimize interference with protein function and are ideal for protein expression and analysis. With a choice of two well characterized fusion tags in the N- or C-terminal format and coverage across three genomes, researchers now have immediate access to versatile protein expression vectors and the broadest, highest quality gene content on the market.

Andrew Farmer, Ph.D., vice president for research and development at Clontech Laboratories, Inc. said, “As leading developers of mammalian expression and protein purification systems, we are pleased to work with transOMIC technologies to provide high quality gene collections expressed using Clontech technologies.”

“As the official archive site for the MGC we are aligned with NIH’s mandate to make gene content easily available to researchers. Even better, we’re adding new functionality to the gold standard cDNA clone collection,” said Gwen Fewell, Ph.D., chief commercial officer for transOMIC technologies. “Providing access to genes previously unavailable in well studied expression systems allows researchers new flexibility with familiar tools.”

For product details or more information about the MGC premier™ Tagged ORF collections see

About transOMIC technologies, inc.

transOMIC technologies is a newly founded biotechnology company focused on providing the life science research market with innovative technologies and research tools to accelerate the quest towards elucidating the complexity of life and human disease. These research tools for gene manipulation provide investigators with high-quality genes, RNAi tools and delivery reagents for gene function analysis in relation to oncology, neuroscience and metabolic disorders.
For more information, visit transOMIC technologies’ website:

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include the Living Colors fluorescent proteins; high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, Takara Bio aims to extend its reach around the world. More information is available at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Migraines Found Linked to Nighttime Teeth Grinding & Clenching in TMJ Treatment Clinical Trial - Holistic Technologies
2. Life Technologies to Present at Leerink Swann Global Healthcare Conference
3. Life Technologies Named #33 among Global 100 Most Sustainable Corporations
4. Life Technologies Acquires BAC BV, Expands Capabilities in Bioprocessing
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Neptune Technologies & Bioressources Inc. To Contact The Firm
6. Statement by Life Technologies Board of Directors
7. Brain State Technologies to Host Open House and Demonstrate Their Revolutionary Technology
8. BioSpecifics Technologies Corp. Investor Presentation Now Available for On-demand Viewing at
9. France & Germany Blood Banking Market: Innovative Technologies and Emerging Business Opportunities in New Research Report at
10. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
11. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
Breaking Biology Technology:
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):